12:00 AM
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ondansetron: Phase II data

Top-line data from a double-blind, North American Phase II trial in 168 OCD patients who had an inadequate response to first-line treatment with a serotonin reuptake inhibitor (SRI) showed that twice-daily 0.5 or 0.75 mg oral TO-2061 as...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >